Shareholding disclosure

Armistice Capital Master Fund Ltd

Declared position

75.76%

Threshold

Crossed upwards

Timeline

Published

13.04.2023

Transaction

03.04.2023

Voting rights breakdown

Voting rights acquired75.76%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAN4B00072

Beneficial owner

Armistice Capital Master Fund Ltd

Declared address

Armistice Capital Master Fund Ltd, New York, NY

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Armistice Capital Master Fund Ltd

Addex Therapeutics Ltd13.04.2023TAN4B00072

Disclosure summary

Armistice Capital Master Fund Ltd disclosed a holding in Addex Therapeutics Ltd on the acquisition side, published by SIX Exchange Regulation on 13.04.2023, at 75.76% of voting rights. Notice category: Single shareholder.

Disclosed position

75.76%

Voting rights acquired

Voting rights acquired75.76%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Armistice Capital Master Fund Ltd disclosed a holding in Addex Therapeutics Ltd, published on 13.04.2023.

Publication date13.04.2023

Transaction date03.04.2023

Issuing companyAddex Therapeutics Ltd

Beneficial ownerArmistice Capital Master Fund Ltd

Declared addressArmistice Capital Master Fund Ltd, New York, NY

CategorySingle shareholder

Voting rights acquired75.76%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAN4B00072

Source: SIX Exchange Regulation · Publication date: 13.04.2023

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open